Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress

Bibliographic Details
Main Authors:	Andreas Lundqvist, Rolf Kiessling, Isabelle Magalhaes, Jonas Mattsson, Stefanie Renken, Takahiro Nakajima, Elias S J Arnér, Stina Linnea Wickström
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/6/e004458.full

Similar Items

Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads
by: Adela Kiessling, et al.
Published: (2022-03-01)

NK cells and solid tumors: therapeutic potential and persisting obstacles
by: Le Tong, et al.
Published: (2022-11-01)

STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells
by: Lu Lu, et al.
Published: (2023-09-01)

The Antitumor Effect of Heparin is not Mediated by Direct NK Cell Activation
by: Gustavo R. Rossi, et al.
Published: (2020-08-01)

Antitumor Immunity: Role of NK Cells and Extracellular Vesicles in Cancer Immunotherapy
by: Angelina E. Prokopeva, et al.
Published: (2023-12-01)

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
by: Thomas Poiret, et al.
Published: (2023-02-01)

Improved Antitumor Effect of NK Cells Activated by Neutrophils in a Bone Marrow Transplant Model
by: Daisuke Nakato, et al.
Published: (2023-01-01)

Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
by: Khang Luu, et al.
Published: (2021-02-01)

T-BET and EOMES sustain mature human NK cell identity and antitumor function
by: Pamela Wong, et al.
Published: (2023-07-01)

Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects
by: Xiao Wang, et al.
Published: (2022-12-01)

Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy
by: Wenjiao Xia, et al.
Published: (2023-04-01)

Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity
by: Pranav Oberoi, et al.
Published: (2020-03-01)

Checkpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8+ T Cells
by: Jiacheng Bi, et al.
Published: (2023-04-01)

Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
by: Thornton W Thompson, et al.
Published: (2017-12-01)

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
by: Hong Luo, et al.
Published: (2019-12-01)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
by: Xinyu Wu, et al.
Published: (2022-12-01)

CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude
by: Thomas Poiret, et al.
Published: (2024-03-01)

Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions
by: Xuejun Fan, et al.
Published: (2022)

Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review
by: Chinmayee Priyadarsini Dash, et al.
Published: (2024-04-01)

Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions
by: Xuejun Fan, et al.
Published: (2022-09-01)

Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
by: Ziqing Chen, et al.
Published: (2019-07-01)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
by: Chan Liao, et al.
Published: (2023-09-01)

CAR-NK Cells in the Treatment of Solid Tumors
by: Ewa Wrona, et al.
Published: (2021-05-01)

ANTI-CD19 CARS ARMED WITH NK RECEPTOR-DERIVED ACTIVATION DOMAINS DEMONSTRATE TO IMPROVE CAR-NK ANTITUMOR EFFECTOR FUNCTION AND ARE DIFFERENTIALLY ENHANCED BY DASATINIB
by: MHD Santos, et al.
Published: (2023-10-01)

329 Redirecting NK cell cytotoxicity by innate cell engagers: a differentiated and innovative approach compared to CAR-NK cells
by: Ivica Fucek, et al.
Published: (2023-11-01)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
by: Yanlin Yu
Published: (2023-04-01)

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
by: Xinghui Xiao, et al.
Published: (2023-04-01)

Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells
by: Cuiying He, et al.
Published: (2022-10-01)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
by: Loredana Cifaldi, et al.
Published: (2023-06-01)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
by: Faezeh Ramezani, et al.
Published: (2023-11-01)

IPSC-derived CAR-NK cells for cancer immunotherapy
by: Xiaotong Lin, et al.
Published: (2023-09-01)

Biomarkers as targets for CAR-T/NK cell therapy in AML
by: Ruonan Shao, et al.
Published: (2023-06-01)

TXNIP Promotes Human NK Cell Development but Is Dispensable for NK Cell Functionality
by: Eva Persyn, et al.
Published: (2022-09-01)

MiRNAs and lncRNAs in NK cell biology and NK/T-cell lymphoma
by: FengXia Gao, et al.
Published: (2021-09-01)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
by: Lara Herrera, et al.
Published: (2021-10-01)

Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
by: Xinghui Xiao, et al.
Published: (2024-01-01)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
by: Marion Arnaud, et al.
Published: (2023-01-01)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
by: Sergey Kulemzin, et al.
Published: (2021-11-01)

Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
by: Eunju Shin, et al.
Published: (2023-07-01)

Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
by: Fan Yang, et al.
Published: (2024-03-01)